KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Net Margin (2016 - 2025)

Inovio Pharmaceuticals' Net Margin history spans 16 years, with the latest figure at 37100.3% for Q1 2025.

  • For Q1 2025, Net Margin changed N/A year-over-year to 37100.3%; the TTM value through Sep 2025 reached 47654.43%, up 804330.0%, while the annual FY2024 figure was 49509.43%, 3326956.0% down from the prior year.
  • Net Margin for Q1 2025 was 37100.3% at Inovio Pharmaceuticals, down from 16682.03% in the prior quarter.
  • Across five years, Net Margin topped out at 412.75% in Q3 2022 and bottomed at 43687.24% in Q4 2022.
  • The 5-year median for Net Margin is 20627.17% (2021), against an average of 22946.68%.
  • The largest YoY upside for Net Margin was 2021442bps in 2022 against a maximum downside of -3094196bps in 2022.
  • A 5-year view of Net Margin shows it stood at 12745.28% in 2021, then crashed by -243bps to 43687.24% in 2022, then skyrocketed by 44bps to 24357.91% in 2023, then soared by 32bps to 16682.03% in 2024, then tumbled by -122bps to 37100.3% in 2025.
  • Per Business Quant, the three most recent readings for INO's Net Margin are 37100.3% (Q1 2025), 16682.03% (Q4 2024), and 31648.39% (Q2 2024).